Division of Hematology and Medical Oncology - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Curr Opin Oncol. 2021 May 1;33(3):206-211. doi: 10.1097/CCO.0000000000000718.
Research and innovation over the past half century have rendered testicular cancer a highly curable malignancy. Challenges and uncertainty remain in several aspects related to the management and surveillance of patients with germ cell tumors (GCT). Long-term effects of treatment on survivors of testicular cancer remain as continued areas of interest. This review aims to highlight pearls and perils in the management of patients with GCT.
Uncertainty remain regarding complex aspects of first-line and salvage treatments of GCT, interpretation of tumor markers in cases of α-fetoprotein levels less than 25 ng/ml, plateau of β-human chorionic gonadotropin (hCG) levels in patients with initial hCG greater than 50 000 mIU/ml, supportive therapies throughout chemotherapy regimens, and long-term survivorship of patients who underwent surgery or received platinum-based chemotherapy. This review aims to highlight challenges that remain in GCT, review the emerging data in these areas, and provide our institutional opinion on the management in several aspects of GCT.
Testicular cancer continues to present challenging clinical scenarios with respect to treatment, surveillance, and long-term management of patients. We review the data and share our institutional knowledge in several challenging areas related to the management of GCT.
在过去的半个世纪中，研究和创新使睾丸癌成为一种高度可治愈的恶性肿瘤。在生殖细胞瘤（GCT）患者的管理和监测的几个方面仍存在挑战和不确定性。治疗对睾丸癌幸存者的长期影响仍然是持续关注的领域。本文旨在强调 GCT 患者管理中的要点和难点。
在 GCT 的一线和挽救治疗的复杂方面仍存在不确定性，在甲胎蛋白水平低于 25ng/ml 的情况下，肿瘤标志物的解释，初始 hCG 大于 50000mIU/ml 时β-人绒毛膜促性腺激素（hCG）水平的平台期，化疗方案中支持性治疗，以及接受手术或铂类化疗的患者的长期生存。本文旨在强调 GCT 中仍然存在的挑战，综述这些领域的新数据，并就 GCT 的几个方面的管理提供我们机构的意见。
睾丸癌在治疗、监测和患者的长期管理方面仍然存在具有挑战性的临床情况。我们回顾了数据，并在与 GCT 管理相关的几个具有挑战性的领域分享了我们的机构知识。
